Key Events This Week
23 Feb: Stock opens at Rs.907.90 with a 0.77% gain
24 Feb: Technical momentum shifts amid mixed indicator signals
26 Feb: Surge in call option activity and open interest amid bullish momentum
27 Feb: Stock closes at Rs.922.50, down 1.67% on the day but up for the week
23 February 2026: Positive Start with Modest Gains
Zydus Lifesciences began the week on a positive note, closing at Rs.907.90, up 0.77% from the previous close of Rs.901.00. This outpaced the Sensex’s 0.39% gain, which closed at 36,817.86. The stock’s volume of 23,005 shares indicated steady investor interest. The initial uptick set a constructive tone for the week, reflecting cautious optimism amid broader market stability.
24 February 2026: Technical Momentum Shifts Amid Mixed Signals
On 24 February, the stock experienced a slight decline of 0.39%, closing at Rs.904.35, while the Sensex fell 0.78% to 36,530.09. This day marked a pivotal shift in Zydus Lifesciences’ technical momentum, moving from bearish to mildly bearish territory. Key indicators such as MACD showed a weekly mild bullish signal contrasting with a monthly mild bearish stance, while RSI remained neutral. Bollinger Bands and moving averages suggested subdued volatility with a mild bearish bias. The stock hovered near its lower Bollinger Band, indicating potential downside pressure despite the modest price movement.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
25 February 2026: Strong Rebound with Significant Gains
The stock rebounded sharply on 25 February, gaining 1.66% to close at Rs.919.40, outperforming the Sensex’s 0.41% rise to 36,679.75. Volume surged to 36,192 shares, signalling renewed buying interest. This recovery was supported by technical factors and growing investor confidence, as the stock moved above key short-term moving averages. The positive momentum suggested a potential shift towards a more sustained rally, despite the cautious technical backdrop.
26 February 2026: Surge in Call Option Activity and Open Interest
On 26 February, Zydus Lifesciences gained 2.04%, closing at Rs.938.15, its weekly high. The stock outperformed its Pharmaceuticals & Biotechnology sector by 1.26% and the Sensex by 0.19%. This day was marked by a significant surge in derivatives activity, with call option contracts at the Rs.950 strike price reaching 4,397 in volume and open interest climbing to 1,144 contracts. The combined futures and options turnover exceeded ₹30,600 lakhs, reflecting heightened market engagement and bullish positioning ahead of the 30 March expiry.
Investor participation was robust, with delivery volumes on 25 February jumping 104.92% above the five-day average, indicating genuine accumulation. The stock traded above its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term strength, though it remained below the 200-day average, highlighting longer-term resistance.
27 February 2026: Profit Taking Amid Market Weakness
The week concluded with a 1.67% decline to Rs.922.50 on 27 February, as the Sensex dropped 1.16% to 36,322.56. Volume moderated to 19,139 shares. Despite the day’s pullback, the stock closed the week with a solid 2.39% gain, significantly outperforming the Sensex’s 0.96% loss. The decline reflected profit-taking following the prior day’s strong rally and increased volatility in the broader market.
Holding Zydus Lifesciences Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Weekly Price Performance: Zydus Lifesciences vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-23 | Rs.907.90 | +0.77% | 36,817.86 | +0.39% |
| 2026-02-24 | Rs.904.35 | -0.39% | 36,530.09 | -0.78% |
| 2026-02-25 | Rs.919.40 | +1.66% | 36,679.75 | +0.41% |
| 2026-02-26 | Rs.938.15 | +2.04% | 36,748.49 | +0.19% |
| 2026-02-27 | Rs.922.50 | -1.67% | 36,322.56 | -1.16% |
Key Takeaways
Positive Signals: Zydus Lifesciences outperformed the Sensex by 3.35% over the week, closing at Rs.922.50. The surge in call option activity and open interest on 26 February indicates strong bullish sentiment and growing investor engagement. The stock’s position above multiple short- and medium-term moving averages supports a constructive technical outlook in the near term.
Cautionary Notes: Despite short-term strength, the stock remains below its 200-day moving average, signalling longer-term resistance. Technical indicators present a mixed picture, with monthly MACD and Bollinger Bands suggesting mild bearishness. The recent downgrade to a Mojo Grade of Sell and a moderate Mojo Score of 48.0 reflect fundamental concerns that temper enthusiasm. Profit-taking on the final trading day highlights potential volatility ahead.
Conclusion
Zydus Lifesciences Ltd demonstrated resilience and relative strength during the week ending 27 February 2026, supported by a combination of technical momentum shifts and heightened derivatives market activity. The stock’s 2.39% weekly gain against a declining Sensex underscores its outperformance amid mixed market conditions. However, the coexistence of bullish short-term signals with cautious longer-term technical and fundamental indicators suggests a nuanced outlook. Investors and traders should closely monitor price action around key resistance levels, particularly the Rs.950 strike price in options markets, and remain attentive to volume and open interest trends as indicators of sustained momentum or potential reversals.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
